Malvaso, Dalma
 Distribuzione geografica
Continente #
NA - Nord America 237
EU - Europa 166
AS - Asia 113
AF - Africa 8
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 529
Nazione #
US - Stati Uniti d'America 232
SG - Singapore 50
SE - Svezia 39
IT - Italia 30
CN - Cina 29
PL - Polonia 25
DE - Germania 19
IE - Irlanda 18
GB - Regno Unito 15
ID - Indonesia 13
IN - India 10
CI - Costa d'Avorio 8
RU - Federazione Russa 6
CA - Canada 5
TR - Turchia 5
AU - Australia 3
GR - Grecia 3
BE - Belgio 2
EU - Europa 2
FI - Finlandia 2
FR - Francia 2
IR - Iran 2
UA - Ucraina 2
ES - Italia 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
MY - Malesia 1
NL - Olanda 1
VN - Vietnam 1
Totale 529
Città #
Chandler 53
Singapore 44
Ashburn 30
Warsaw 25
New York 24
Dublin 18
Jakarta 13
Milan 12
Abidjan 8
Bremen 8
San Mateo 8
Fairfield 7
Beijing 5
Boston 5
Hyderabad 5
Moscow 5
Princeton 5
Seattle 5
Wilmington 5
Englewood 4
Frankfurt am Main 4
Hefei 4
London 4
Ankara 3
Ann Arbor 3
Asansol 3
Athens 3
Augusta 3
Boydton 3
Camden 3
Dreieich 3
Houston 3
Padova 3
Ragusa 3
Redmond 3
Rome 3
Sydney 3
Boardman 2
Brussels 2
Cambridge 2
Chiswick 2
Collegeville 2
Landsberg am Lech 2
Lappeenranta 2
Montreal 2
Ottawa 2
Paris 2
Pinner 2
Redwood City 2
Shanghai 2
Southampton 2
Washington 2
Acton 1
Bethesda 1
Budapest 1
Catania 1
Dong Ket 1
Esslingen am Neckar 1
Guangzhou 1
Istanbul 1
Kilburn 1
Kish 1
Kuala Lumpur 1
Laurelton 1
Leawood 1
Madrid 1
Miami 1
Mykolayiv 1
Prineville 1
Pune 1
Rosmalen 1
Tokyo 1
Toronto 1
Trieste 1
White Salmon 1
Woodbridge 1
Totale 397
Nome #
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature 114
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 81
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 51
PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa 49
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 39
Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study 37
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 34
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 34
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 28
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 25
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 22
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 17
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 9
Totale 540
Categoria #
all - tutte 3.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.491


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 0 0 0 0 0 2 8 2
2020/202151 3 4 7 2 6 4 5 8 5 3 3 1
2021/202257 1 0 2 5 5 7 2 14 1 3 10 7
2022/2023167 11 15 9 21 12 21 8 17 31 3 10 9
2023/2024184 11 26 11 20 10 36 11 12 3 4 24 16
2024/202569 8 4 22 8 27 0 0 0 0 0 0 0
Totale 540